Pfizer(US:PFE) 智通财经网·2025-06-30 03:34Core Insights - Pfizer's new antibacterial drug, Sifonuo® (injection of amikacin and avibactam), has been officially approved by the National Medical Products Administration for treating complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) caused by Gram-negative bacteria [1][2] Group 1 - Sifonuo® is the first β-lactam/β-lactamase inhibitor combination that covers all enzyme types of carbapenem-resistant Enterobacteriaceae (CRE), effectively targeting KPC and OXA-48 carbapenemases, and addressing the issue of MBL-producing bacteria [1] - The drug's broad-spectrum enzyme inhibition activity not only improves patient treatment outcomes but also reduces the risk of antibiotic resistance [1] - The approval of Sifonuo® is significant for public health and innovative treatment paradigms, as it helps combat the trend of bacterial resistance and enhances precise coverage against CRE infections [1] Group 2 - Pfizer's China President, Jean-Christophe Pointeau, emphasized the global challenge of antibiotic resistance and the company's commitment to developing innovative anti-infective drugs to address resistant bacterial infections [2] - The approval of Sifonuo® expands the treatment options for carbapenem-resistant Gram-negative bacteria (CRO) and provides innovative solutions for targeted therapy, benefiting more patients [2] - Pfizer expresses gratitude to the National Medical Products Administration and other relevant departments for their support of new antibacterial drugs, reaffirming its mission to bring breakthrough innovations that change patients' lives [2]